Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2020)
Historic Enterprise Value for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to -$18.0 million.
- Monopar Therapeutics' Enterprise Value fell 30010.04% to -$18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$18.0 million, marking a year-over-year decrease of 30010.04%. This contributed to the annual value of -$13.2 million for FY2019, which is 9170.7% down from last year.
- As of Q3 2020, Monopar Therapeutics' Enterprise Value stood at -$18.0 million, which was down 30010.04% from -$12.5 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Enterprise Value registered a high of -$2.9 million during Q4 2016, and its lowest value of -$18.0 million during Q3 2020.
- In the last 5 years, Monopar Therapeutics' Enterprise Value had a median value of -$7.9 million in 2018 and averaged -$8.4 million.
- As far as peak fluctuations go, Monopar Therapeutics' Enterprise Value skyrocketed by 4100.31% in 2019, and later tumbled by 30010.04% in 2020.
- Monopar Therapeutics' Enterprise Value (Quarter) stood at -$2.9 million in 2016, then plummeted by 240.48% to -$9.8 million in 2017, then rose by 29.54% to -$6.9 million in 2018, then crashed by 91.71% to -$13.2 million in 2019, then plummeted by 36.09% to -$18.0 million in 2020.
- Its Enterprise Value stands at -$18.0 million for Q3 2020, versus -$12.5 million for Q2 2020 and -$12.6 million for Q1 2020.